Accuray Incorporated
ARAYHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeAccuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America,. The company carries a $29.8M market cap, placing it firmly in the micro-cap category. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Market Cap
$29.8M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-1.04
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.24
ROE
-101.1%
ROA
-1.7%
Cash
$38.1M
Total Debt
$182.4M
Free CF
-$10.9M
52W Change
-81.6%
Annual Financials
Cash vs Debt
Where ARAY stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ARAY finished 50.94% below its 150-day moving average ($0.53) and 65.33% below its 200-day moving average ($0.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARAY overbought or oversold?
At the July 15, 2026 close, ARAY's RSI(14) was 32.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ARAY has $38.1M in cash with $182.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$10.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -101.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $429.9M (2022) to $458.5M (2025).
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARAY.